New technology could take out some of the pain -- and subjectivity -- for those looking to invest in this emerging line of treatments.
ABT reported its third quarter financial performance on Wednesday morning.
Let's take a look at the charts and indicators.
Let's check on the charts and indicators.
Let's review the charts and indicators.
Here's our price objective for now.
Investors are increasingly looking to the companies involved in clinical trials. Here are six favorite names in this space.
The current candidates for the 2022 Tax-Loss Selling Recovery Portfolio are few and far between, with only a couple households names in the bunch.
The economics of this space is not nearly as favorable as the outcomes these drugs achieve in medical settings.
ProQR Therapeutics, Oscar Health and Hims & Hers Health appear to have promising futures.